CD4 and AIDS: The present study conducted among cohorts in different sites from 6 Latin-American countries shows that a significant proportion of patients starting HAART in this region do so after they have experienced an AIDS-defining illness or when the CD4 cell count is lower than 200, far below the cutoff of 350 cells/mm3 that is the recommended by most of the current international guidelines [30]–[32].